A retrospective review of the persistence of bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.

Share on facebook
Share on twitter
Share on linkedin

Authors: Graeme Jones, Stephen Hall, Paul Bird, Geoff Littlejohn, Kathleen Tymms, Peter Youssef, Eric Chung, Rina Barrett, Peter Button
International Journal of Rheumatic Diseases 2018; 21: 1581–1590

Related articles

Are high coronary risk patients missing ou...

To examine whether high coronary risk patients in Australia, where use of lipid-lowering drugs (LLD) is very high by international standards, are receiving LLD.

A retrospective review of the persistence ...

Aim: To describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Australian rheumatoid arthritis (RA) patients, and assess the influence of methotrexate and other conventional DMARD (cDMARD) concomitant me...